AFreeze

No name

AFreeze is a medical device company dedicated to improve the treatment for patients with cardiac arrythmias. Our products are designed to improve patient’s lives and their health ...

The CoolLoop® catheter is a true single shot device, allowing the electrophysiologist to perform endocardial ablation in a simple…

AFreeze is a medical device company dedicated to improve the treatment for patients with cardiac arrythmias. Our products are designed to improve patient’s lives and their health.
With deep ties to the Medical University of Innsbruck and the UMIT - Private University of Health Sciences, Medical Informatics and Technology, the scientific concept behind AFreeze’s products emerged in the mid-2000 years.
By using cryoenergy to induce distinct lesions in coronary heart tissue, a safe, well tolerated treatment option for cardiac arrhythmias can be established. AFreeze’s flagship product is the CoolLoop@ cryoablation system for the treatment of atrial fibrillation. It is a safe, efficient and very easy to use device, designed to simplify the catheter ablation procedure and to improve the therapeutic outcome for atrial fibrillation.

The AFreeze team is dedicated to bringing better treatment options to patients suffering from atrial fibrillation …

The CoolLoop® cryoablation system is developed to treat atrial fibrillation (AF) by catheter ablation. It consists of a console and a catheter. Introduction of the catheter is aided by a steerable sheath.

The CoolLoop® catheter is a true single shot device, allowing the electrophysiologist to perform endocardial ablation in a simple…

The CoolLoop® cryoablation catheter targets a significant market: Atrial fibrillation (AF) is the most common cardiac rhythm disease today. More than 14 million people in the industrialized world are affected by AF. AF affects 1–2% of the population, and its prevalence is estimated to at least double in the next 50 years as the population ages. The prevalence of AF increases with age, from 0.5% at 40–50 years, to 5–15% at 80 years. The lifetime risk of developing AF is approximately 25% in those who have reached the age of 40.

AF is associated with increased rates of death, stroke and other thrombo-embolic events, heart failure and hospitalizations, impaired quality of life, reduced exercise capacity, and left ventricular dysfunction. Death rates are doubled by AF, independently of other known predictors of mortality. Stroke in AF is often severe and results in long-term disability or death. Approximately every fifth stroke is due to AF. Quality of life and exercise capacity are impaired in patients with AF. Patients with AF have a significantly poorer quality of life compared with healthy controls, the general population, or patients with coronary heart disease in sinus rhythm. Hospitalizations due to AF account for one-third of all admissions for cardiac arrhythmias and thus pose a significant economic burden to the healthcare system.

Current therapies focus on pharmaceutical drugs to maintain sinus rhythm. However, these do not address the underlying cause of the disease, have limited therapeutic effect and side effects. Over the last decade, catheter ablation has emerged as a minimally invasive treatment option. By developing safe, efficient and simple tools, AFreeze will provide physicians, patients and hospitals with new treatment options that really make a difference.

Disclaimer: Investigational device. Regulatory approval of the AFreeze cryoablation system is pending and is presently not for sale in any territory..

Every patient who presents with AF for the first time is considered a patient with first diagnosed AF, irrespective of the duration of the arrhythmia …

Today catheter ablation of rapid irregular heartbeat (tachyarrhythmia) is already a standard procedure for treating many forms of tachyarrhythmia. It is in fact the only way…

The underlying principle of Cryoablation is the Joule-Thomson-Effect, where a refrigerant usually under high pressure in liquid form is allowed to expand suddenly through a porous plug into vacuum. This effect is used in the CoolLoop® catheter to create circular lines of lesions in the human atrium, in order to achieve debulking of the atria for prevention of AF.

Cryoablation comprises all methods of destroying tissue by freezing. Reactions induced may range from inflammation to destruction of tissue depending on the severity of the freezing injury. Tissue destruction in turn is based on two mechanisms: direct cell injury and vascular stasis.

As the CoolLoop catheter rapidly absorbs heat from the tissue, ice crystals form within the cells. This leads to immediate cell …